United States FDA Warns Companies and Researchers Against Suppressing Unfavourable Trial Results

Summarized in a recent FDA news release, the warning follows concerns that many study sponsors are failing to disclose negative or unfavorable findings, creating gaps in publicly available evidence. According to the FDA, this lack of transparency leads to publication bias, where successful outcomes are overrepresented and failures are hidden, distorting perceptions of drug safety and effectiveness.

An internal FDA analysis found that nearly 30 percent of studies likely subject to mandatory reporting rules had not submitted results. These rules apply to certain interventional trials involving FDA-regulated products with a United States connection, though early-stage and device feasibility studies are excluded. FDA Commissioner Marty Makary has criticized the practice of withholding negative data, saying that trial sponsors have an ethical duty to make all results public, regardless of commercial implications, so that clinicians and researchers can make fully informed decisions.

To address the issue, the FDA recently sent notices covering more than 3,000 trials, urging voluntary compliance before considering enforcement actions such as formal non-compliance notices. Officials say the initiative is intended to improve transparency, strengthen patient safety, and ensure that both the medical community and the public have access to complete and accurate information about the benefits and risks of medical products.

To learn how the side effects of prescription drugs are now a leading cause of death in the industrialized world, see ‘The Laws of the Pharmaceutical Industry’ feature on our website.